Trials / Recruiting
RecruitingNCT03899155
Pan Tumor Rollover Study
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,500 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Ipilimumab | Specified dose on specified days |
| DRUG | Cabozantinib | Specified dose on specified days |
| DRUG | Trametinib | Specified dose on specified days |
| DRUG | Relatlimab | Specified dose on specified days |
| DRUG | Nivolumab + Relatlimab | Specified dose on specified days |
| DRUG | Capecitabine | Specified dose on specified days |
| DRUG | Bevacizumab | Specified dose on specified days |
| DRUG | Temozolomide | Specified dose on specified days |
| DRUG | Rucaparib | Specified dose on specified days |
| DRUG | Daratumumab | Specified dose on specified days |
| DRUG | Regorafinib | Specified dose on specified days |
| DRUG | Leucovorin | Specified dose on specified days |
| DRUG | Fluorouracil | Specified dose on specified days |
| DRUG | Oxaliplatin | Specified dose on specified days |
| DRUG | Enzalutamide | Specified dose on specified days |
| DRUG | Sunitinib | Specified dose on specified days |
| DRUG | Pemetrexed | Specified dose on specified days |
| DRUG | Pembrolizumab | Specified dose on specified days |
Timeline
- Start date
- 2019-08-09
- Primary completion
- 2029-08-25
- Completion
- 2029-08-25
- First posted
- 2019-04-02
- Last updated
- 2026-04-01
Locations
399 sites across 38 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03899155. Inclusion in this directory is not an endorsement.